142816-70-4

Upstream product

• 98-88-4 benzoyl chloride 
• 122111-03-9 gemcitabine hydrochloride 
• 95058-81-4 gemcitabine 

Downstream Products

• 608122-30-1 N-benzoyl-5'-O-(tert-butyldimethylsilyl)-2'-deoxy-2',2'-difluorocytidine 
• 95058-81-4 gemcitabine 
• 1365255-30-6 C₁₆H₁₃F₂IN₆O₄ 
• 1145869-48-2 1-(4-N-benzoyl-2',5'-dideoxy-2',2'-difluoro-β-D-pent-4-enoribofuranosyl)cytosine 
• 142808-44-4 5'-O-(4,4'-dimethoxytrityl)-3'-O-(2-cyanoethyl-N,N'-diisopropylphosphoramidite)-N⁴-benzoyl-2'-deoxy-2',2'-difluorocytidine 
• 1145869-47-1 1-(4-N-benzoyl-2'-dideoxy-2',2'-difluoro-5'-iodo-β-D-ribofuranosyl)cytosine 
• 608122-33-4 (N-benzoyl-2'-deoxy-2',2'-difluoro-3-acetyl-5'-monophosphate-1-dodecylthio-2-decyloxypropyl)cytidine 
• 608122-31-2 N-benzoyl-5'-O-(tert-butyldimethylsilyl)-2'-deoxy-2',2'-difluoro-3-acetylcytidine 
• 608122-32-3 N-benzoyl-2'-deoxy-2',2'-difluoro-3-acetylcytidine 

Relevant academic research and scientific papers

Oligomer-nucleoside phosphate conjugates

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number administration routes, exhibits advantages ove

Azido nucleosides and nucleotide analogs

Disclosed herein are 4′-azido-substituted nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of 4′-azido-substituted nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a 4′-azido-substituted nucleoside, a nucleotide and/or an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.

COMPOSITION CONTAINING MODIFIED DERIVATIVES OF A CYTIDINE ANTIMETABOLITE FOR THE TREATMENT OF SUSCEPTIBLE DISEASE

The present invention relates to homo-oligomeric derivatives of a cytidine antimetabolite and its use for the treatment of susceptible diseases. The cytidine antimetabolite is preferably a compound made of 2-20 units of dFdC linked with 5' - 3' phosphate

Biological and physicochemical characterization of siRNAs modified with 2',2'-difluoro-2'-deoxycytidine (gemcitabine)

The use of synthetic short interfering RNAs (siRNAs) is currently a method of choice to manipulate gene expression in mammalian cells. Efforts aimed at improving siRNA biological activity, including increased silencing properties, higher substrate specifi

Novel oligonucleotides and related compounds

The present invention relates generally to oligonucleotides and more specifically to oligonucleotides which have a sequence including at least two CDG dinucleotides and a prodrug of an antimetabolite. The prodrug can be part of a CpG dinucleotide or may be attached elsewhere on the oligonucleotide.